









Markets
/
Stocks
/
nasdaq-tech
/

Bio-Techne Corp

TECH

62.000USD

-0.020-0.03%

Close 10/29, 16:00（ET）Quotes delayed by 15 min

9.61BMarket Cap

130.97P/E TTM



Bio-Techne Corp

62.000

-0.020-0.03%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Bio-Techne Corp

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bio-Techne Corp's Score

Industry at a Glance

Industry Ranking

46 / 407

Overall Ranking

133 / 4623

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 17 analysts

Buy

Current Rating

66.556

Target Price

+4.09%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Bio-Techne Corp Highlights

StrengthsRisks

Bio-Techne Corporation is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities. The Company's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 68.69%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 68.69%.

Overvalued

The company’s latest PE is 133.17, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 161.69M shares, decreasing 4.59% quarter-over-quarter.

Held by Wallace Weitz

Star Investor Wallace Weitz holds 802.15K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-29

The company's current financial score is 8.38, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 316.96M, representing a year-over-year increase of 3.55%, while its net profit experienced a year-over-year increase of 143.62%.

Score

Industry at a Glance

Previous score

8.38

Change



Financials

9.32

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

2.80

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

9.80

Key Metrics

Free cash flow

No Data

Bio-Techne Corp's Company Valuation

Currency: USD Updated: 2025-10-29

The company’s current valuation score is 4.22, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is 133.17, which is 6.51% below the recent high of 141.84 and 74.67% above the recent low of 33.73.

Score

Industry at a Glance

Previous score

4.22

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 46/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-29

The company’s current earnings forecast score is 8.12, which is higher than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Bio-Techne Corp is 66.00, with a high of 75.00 and a low of 53.00.

Score

Industry at a Glance

Previous score

8.12

Change

Support & Resistance

No Data

Analyst Rating

Based on 17 analysts

Buy

Current Rating

66.556

Target Price

+4.09%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

520

Total

Median

Average

Company name

Ratings

Analysts

Bio-Techne Corp

TECH

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-29

The company’s current price momentum score is 7.07, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 66.70 and the support level at 57.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.02

Change

-1.95

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.101

Neutral

RSI(14)

55.306

Neutral

STOCH(KDJ)(9,3,3)

41.415

Sell

ATR(14)

1.995

Low Volatility

CCI(14)

4.244

Neutral

Williams %R

54.226

Neutral

TRIX(12,20)

0.651

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

64.435

Sell

MA10

63.542

Sell

MA20

61.960

Buy

MA50

56.989

Buy

MA100

54.905

Buy

MA200

56.947

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-29

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.21. The latest institutional shareholding proportion is 103.85%, representing a quarter-over-quarter decrease of 1.48%. The largest institutional shareholder is The Vanguard, holding a total of 18.40M shares, representing 11.82% of shares outstanding, with 1.35% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

18.40M

-0.33%

BlackRock Institutional Trust Company, N.A.

8.79M

-5.50%

T. Rowe Price Associates, Inc.

Star Investors

8.62M

-22.68%

State Street Investment Management (US)

5.86M

-10.28%

Atlanta Capital Management Company, L.L.C.

4.29M

+15.41%

Geode Capital Management, L.L.C.

4.06M

-0.75%

Invesco Capital Management LLC

Star Investors

3.24M

+9.28%

Select Equity Group, L.P.

2.92M

-45.59%

Mairs and Power, Inc.

Star Investors

2.87M

+2.46%

Baron Capital Management, Inc.

Star Investors

2.80M

-14.67%

Risk Assessment

Currency: USD Updated: 2025-10-29

The company’s current risk assessment score is 6.82, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.52. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.